Back to today’s briefing

Story perspectives

Virginia Tech Targets PRMT5 to Revolutionize Cancer Treatment

8/2/2025

23 4

Summary

Story summary

Virginia Tech's Fralin Biomedical Research Institute has made a groundbreaking discovery, pinpointing PRMT5 as a key target for treating stubborn lung, brain, and pancreatic cancers. By pairing PRMT5 inhibitors with MAP kinase pathway blockers, researchers have found a way to enhance treatment effectiveness, potentially transforming the lives of 80,000 to 100,000 cancer patients in the U.S. Further clinical trials are on the horizon.

1 of 1

Story summary

Virginia Tech's Fralin Biomedical Research Institute has made a groundbreaking discovery, pinpointing PRMT5 as a key target for treating stubborn lung, brain, and pancreatic cancers. By pairing PRMT5 inhibitors with MAP kinase pathway blockers, researchers have found a way to enhance treatment effectiveness, potentially transforming the lives of 80,000 to 100,000 cancer patients in the U.S. Further clinical trials are on the horizon.